Morgan Lewis Advises UniQure in $345 Million Public Equity Offering

LONDON, October 3, 2025: Morgan Lewis represented uniQure N.V. in a public offering of 6,736,841 ordinary shares at a price of $47.50 per share (including 947,368 ordinary shares issued pursuant to the exercise of an option granted to the underwriters), as well as pre-funded warrants to purchase 526,316 of its ordinary shares to certain investors. The gross proceeds to the company were approximately $345 million.

uniQure is advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.

Partners Tim Corbett, Louis Beardell, Jacqueline Berman, Scott Memmott, Richard Zarin, and Charles Bogle and associates Anna Voremberg Ellement, Shabeena Sharak and David Bionghi advised uniQure.

For more, read uniQure’s announcement.